Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma : results of 2 european organization for research  and treatment of cancer randomized trials with Mitomycin C and Doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment by Bouffioux, C. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/20460
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
0022-5347/95/1533-0934$03.00/0
The J ournal of Urology
Copyright © 1995 by American Urological Association, Inc.
Vol. 153, 934-941, March 199t
Printed in U.S.A.
INTRAVESICAL ADJUVANT CHEMOTHERAPY FOR SUPERFICIAL 
TRANSITIONAL CELL BLADDER CARCINOMA: RESULTS OF 2 
EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF 
CANCER RANDOMIZED TRIALS WITH MITOMYCIN C AND  
DOXORUBICIN COMPARING EARLY VERSUS DELAYED 
INSTILLATIONS AND SHORT-TERM VERSUS LONG-TERM TREATMENT
Ch. BOUFFIOUX, K H. KURTH, A. BONO, W. OOSTERLINCK, C. BOEKEN KRUGER, M. DE PAUW, 
R. SYLVESTER a n d  THE MEMBERS OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND
TREATMENT OF CANCER GENITOURINARY GROUP*
From the University Hospital, Liege, University Hospital, Ghent and European Organization for Research and Treatment of Cancer Data 
Center, Brussels, Belgium, AMC, Amsterdam and Zuiderziekenhuis, Rotterdam, The Netherlands and Ospedale Circolo, Varese, Italy
ABSTRACT
The European Organization for Research and Treatment of Cancer genitourinary group has 
completed 2 parallel prospective randomized studies, one with 30 mg. mitomycin C and the other 
with 50 mg. doxorubicin as adjuvant intravesical treatment after transurethral resection of 
superficial transitional cell bladder carcinoma. These studies were designed to compare early 
(the day of resection) versus delayed (between 7 and 15 days after resection) instillations and 
short-term (6 months) versus long-term (12 months) treatment. The results indicate that in 
regard to recurrence rate patients having a delayed and short-term treatment do worse than 
those having early instillations (for 6 or 12 months) or those having prolonged treatment (either 
immediate or delayed). With an average followup of 4 years survival, progression beyond T1 
disease, development of distant métastasés and appearance of a second primary were not 
influenced by the therapeutic regimen. A multivariate analysis of prognostic factors is presented, 
which indicates that after adjustment for these factors, patients in the delay, no maintenance 
arm have a significantly higher recurrence rate than the other patients.
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Administration of adjuvant intravesical chemotherapy or 
immunotherapy is a common practice today for the prophy­
laxis of recurrent superficial bladder cancer. Among the dif­
ferent agents used for this purpose, thiotepa, mitomycin C 
and doxorubicin have been shown to be active.1 Regimens 
based on these adjuvant treatments have often been estab­
lished on an empirical basis, and are a compromise between 
potential toxic effects and aimed benefits. Many questions 
still remain unanswered in relation to the scheme of instil­
lation. When is the ideal time to start the treatment? What is 
the ideal dosage at each instillation? What is the optimal 
duration of the treatment? What is the ideal interval between
2 instillations?2
In 1983 the genitourinary group of the European Organi­
zation for Research and Treatment of Cancer (EORTC) 
started 2 parallel trials, one with mitomycin C (protocol
30831) and one with doxorubicin (protocol 30832) to try to 
answer 2 questions: 1) what is the best time for initiation of 
adjuvant intravesical treatment and 2) how long should the 
drug be administered for prophylactic purpose after complete 
transurethral resection of superficial bladder cancer? The 
final results of these 2 studies are reported.
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MATERIALS AND METHODS
Objectives of the study . These 2 randomized clinical trials 
were designed to compare immediate instillations versus de­
layed instillations and short-term versus long-term treat­
ment of mitomycin C (30831) or doxorubicin (30832) given 
intravesically after transurethral resection of superficial 
transitional cell carcinoma of the bladder with respect to 
duration of disease-free interval, recurrence rate including 
evaluation of the number of recurrent tumors, percentage of 
patients with an increase in the T category greater than Tl, 
percentage in whom distant metastases develop, percentage 
in whom a second primary tumor develops and duration of 
survival.
Patient selection. Criteria for patient selection were similar 
to those used by the EORTC genitourinary group in previous 
superficial bladder cancer trials.3 All patients with com­
pletely resectable, stage Ta or Tl (0 or A), papillary transi­
tional cell carcinoma of the bladder (single or multiple, pri­
mary or recurrent) were eligible for the 2 trials. Due to the 
early treatment pathological evaluation was not available at 
randomization and if tumors were not Ta or T l patients were 
ineligible. Previous intravesical treatment with cytotoxic 
drugs was allowed (except for mitomycin C in 30831 and 
doxorubicin in 30832) provided there was at least a 3-month 
interval between the end of the previous treatment and the 
start of protocol treatment.
Criteria for exclusion were the presence of another cancer, 
previous treatment with local or systemic chemotherapy 
within 3 months of randomization, previous treatment with 
mitomycin C (30831) or with doxorubicin (30832), local ra­
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diotherapy within 12 months of randomization, patient gen­
eral condition such th a t survival of 3 years was unlikely, 
expected difficulties of followup, blood urea or creatinine 
level increased more than  50% above the upper normal limit, 
white blood count less than  3,000/mm.3 and/or platelet count 
less than  100,000/mm.3 and untreated urinary tract infec­
tion.
Design o f the trial. After transurethral resection, patients 
were centrally randomized at the EORTC data center to 
receive early or delayed instillations with stratification by 
institution. The choice of the drug was initially optional but 
each center had to adhere to its initial choice for the entire 
period of the study.
Protocol 30831: After endoscopic examination or immedi­
ately after transurethral resection patients were randomly 
assigned to receive early (on day 0) or delayed (between 7 and 
15 days after transurethral resection) instillations of 30 mg. 
mitomycin C. The drug was instilled into the bladder in 50 
ml. saline and retained for a t least 1 hour. Instillations were 
given every week for 4 weeks and then every month for 5 
months (a total of 9 instillations). After 6 months of treat­
ment patients were randomized a second time between main­
tenance treatment, which consisted of 6 further instillations 
(1 every month for 6 months, total 15 instillations) or no 
maintenance (discontinue adjuvant treatm ent after the 9 
initial instillations). Followup cystoscopy was performed ev­
ery 3 months and if there was recurrence during treatment, 
the lesions were resected and the treatm ent was continued 
without any change to fulfill the initial regimen. Hemoglobin, 
white blood count and platelets, blood urea, creatinine, uri­
nalysis and urine cytology had to be determined at each 
followup cystoscopy.
Protocol 30832: Patients were randomly assigned to re­
ceive early (day 0) or delayed (between days 7 and 15 after 
transurethral resection) instillations of 50 mg. doxorubicin. 
The remaining design of the protocol was identical to 30831.
Followup. All patients were to be followed until the second 
recurrence after randomization. Recurrences were detected 
by cystoscopy repeated every 3 months during year 1, every 4 
months during year 2 and every 6 months thereafter (provid­
ed there was no recurrence in the meantime), and findings 
had to be confirmed by biopsy. After the second recurrence or 
if progression in stage to greater than  T1 was documented, 
the patient was followed only for progression and survival, 
with further treatm ent at the urologist’s discretion.
Criteria o f evaluation. The disease-free interval (time to 
first recurrence) was defined as the total time between ran­
domization at entry and the date of the first positive biopsy. 
Patients without recurrence were censored at the date of the 
last cystoscopic examination. The recurrence rate in a group 
of patients was defined as the total number of positive cys­
toscopies divided by the number of years of followup in that 
group (followup began a t the initial randomization and ended 
at the last cystoscopy). All recurrences were histologically 
documented and initial biopsies were reviewed by a referee 
pathologist. The grading system recommended by the Inter­
national Union Against Cancer (grades 1 to 3) was used and 
the staging was based on the tumor, nodes and metastasis 
system (Geneva, 1982). The duration of survival and percent­
age of patients with local or distant progression or a second 
primary tumor were also evaluated.
Statistical methods. The time to first recurrence and dura­
tion of survival were estimated using the Kaplan-Meier prod­
uct limit estimate and compared using the log rank test. For 
ordered variables with more than  2 categories a log rank test 
for trend was used. In order to account for the number and 
frequency of recurrences th a t were noted, the recurrence rate 
was also calculated and compared using a nonparametric 
permutation test. The relative prognostic importance of var­
ious factors on the recurrence rate was studied in a multiva­
riate linear logistic regression model taking as an end point
the number of positive cystoscopies divided by the total num­
ber of cystoscopies.
RESULTS
Clinical material From August 1983 until January 1986, 
965 patients were entered in these 2 studies, including 517 in 
protocol 30831 and 448 in protocol 30832. A total of 483 
patients was randomized to early treatment and 482 to de­
layed treatment. A total of 625 patients was randomized a 
second time, including 312 to maintenance and 313 to no 
maintenance. There were 113 patients (60 in 30831 and 53 in
30832) ineligible for the study because of incorrect T category 
or cell type (86), distant metastases or second malignancy (6), 
previous treatment with mitomycin C or doxorubicin (6) and 
miscellaneous reasons (15). Of the 852 remaining patients no 
information was available for 18 in protocol 30832, thus 
leaving 834 patients for whom at least information at entry 
on study was available, including 457 entered by 28 institu­
tions in protocol 30831 and 377 entered by 20 institutions in 
protocol 30832. Table 1 provides the distribution of the 834 
eligible patients by treatment group. Of the patients 215 
were not randomized a second time (after 6 months) because 
of inter current death, progression or second recurrence (60), 
loss to followup (64), toxicity (20), treatment refusal (18), 
protocol violation or other reasons (53).
Patient characteristics at entry on study. Characteristics a t 
entry on study for the 834 eligible patients are given by 
protocol in table 2. While the patient characteristics were 
well balanced in the different treatment groups, table 2 shows 
that patients entered in protocol 30831 generally tended to 
have a worse prognosis than those entered in 30832. There was 
a higher percentage of recurrent cases (72% versus 37%) and 
recurrent cases with a prior recurrence rate of greater than 
1 recurrence per year (41% versus 15%). Patients in 30831 
also tended to have more tumors at entry on study (32% 
versus 16% had more than 3 tumors at entry) but they also 
had a slightly higher incidence of Ta tumors (63% versus 
51%).
Toxicity. Local toxicity (cystitis) was a minor problem in 
both studies. In 30831 bacterial and chemical cystitis neces­
sitated delay or discontinuation of mitomycin C in 25 of 449 
patients (6%). The incidence of chemical cystitis requiring an 
arrest of treatment was higher in the early instillation 
scheme (3%) than in the delayed scheme (0%). In 30832 
bacterial and/or chemical cystitis requiring a delay or discon­
tinuation of treatment occurred in 34 of 368 patients (9%). 
The incidence of chemical cystitis requiring discontinuation 
of treatment was higher in the early instillation scheme 
(2.2%) than in the delayed scheme (0.5%).
Systemic toxicity was never life threatening. In 30831 al­
lergic reactions were reported by 31 of 449 patients (7%), 
including 19 (4.2%) in whom these reactions were mild and 
did not require any alteration of instillation treatment, while 
in 8 (1.8%) the severity of the reaction required discontinu­
ation of the instillations. In 30832 systemic toxicity was 
reported in 26 of 368 patients (7.1%) requiring discontinua-
Table 1. Number of eligible patients by treatment group
Protocol Treatment 30831 Mitomycin C
30832
Doxorubicin
Total 
Mitomycin C + 
Doxorubicin
First randomization:
Early 228 189 417
Delayed 229 188 417
Totals 457 377 834
Second randomization:
No maintenance 171 143 314
Maintenance 165 140 305
Not randomized 121 94 215
Totals 457 377 834
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No. Mitomycin C No. 30831 No. 30832
and Doxorubicin Mitomycin C Doxorubicin
(%) (%) (%)
T category: 
Ta 479 (57.4) 287 (62.8) 192 (50.9)
Tl 374 (41.2) 162 (35.4) 182 (48.3)
Tis 9 (1.1) 6 (1.3) 3 (0.8)4  mm
TO 1 (0.1) 1 (0.2) 0 (0.0)»^r
Tx 1 (0,1) 1 (0.2) 0 (0.0)
Grade:
2 (0.5)GO 5 (0.6) 3 (0.7)
G1 341 (40.9) 178 (38.9) 163 (43.2)
G2 377 (45.2) 218 (47.7) 159 (42.2)
G3 105 (12.6) 56 (12.3) 49 (13.0)
Gx 6 (0.7) 2 (0.4) 4 (1.1)
Tumor size (cm.):
123 (32.6)Less than 1 305 (36.6) 182 (39.8)
1-2.9 388 (46.5) 205 (44.9) 183 (48.5)
Greater than 3 139 (16.7) 70(15.3) 69 (18.4)
Unknown 2 (0.2) 0 (0.0) 2 (0.5)
No. tumors:
232 (61.5)1 433 (51.9) 201 (44.0)
2—3 196 (23.5) 112 (24.5) 84 (22.3)
Greater than 3 205 (24.6) 144 (31.5) 61 (16.2)
Prior recurrence rate/yr.:
238 (63.1)Primary 367 (44.0) 129 (28.2)
Recurrent: 467 (56.0) 328 (71.8) 139 (36.9)
Less than 1 221 (26.5) 140 (30.6) 81 (21.5)
Greater than 1 245 (29.4) 187 (40.9) 58 (15.4)
Unknown 1 (0.1) 1 (0.2) 0 (0.0)
Sex;
M 674 (80.8) 356 (77.9) 318 (84,4)
F 160 (19.2) 101 (22.1) 59 (15.6)
Age:
39 (10.3)Less than 50 68 (8.2) 29 (6.3)
50-59 171 (20.5) 104 (22.8) 67 (17.8)
60-69 280 (33.6) 151 (33.0) 129 (34.2)
70-79 256 (30.7) 140 (30.6) 116 (30.8)
Greater than 80 59 (7.1) 33 (7.2) 26 (6.9)
Overall 834 (100) 457 (100) 377 (100)
tion of the instillations on 3 occasions only (0.8%). Toxicity 
included mainly cutaneous prurit, dizziness and malaise.
Of the 834 eligible patients no followup for recurrence was 
available for 82. Thus, the efficacy analyses for time to first 
recurrence, recurrence rate and tumor invasion (greater than 
Tl) are based on the 752 eligible patients for whom followup 
cystoscopy was available. Analyses of distant metastases, 
second primaries and survival are based on the 824 patients 
for whom followup of any type was available.
Disease-free interval (time to first recurrence). Based on an 
average followup of 2.75 years 161 of 374 patients (43%) on 
early treatment had at least 1 recurrence compared to 187 of 
378 (49%) on delayed treatment. Comparison of the time to 
first recurrence based on a 2 sided log rank test was not signif­
icant (p = 0.18). Followup data after the second randomization 
were available for 617 of the 619 patients randomized a second 
time. Based on an average followup of 3 years 156 of 314 
patients (50%) not receiving maintenance and 130 of 303 
(43%) on maintenance had recurrence. The difference in time 
to first recurrence is not significant (p = 0.20). Figure 1 
presents the time to first recurrence according to the differ­
ent cross classifications of the treatment groups. For patients 
who were randomized a second time there was no significant 
difference in the time to first recurrence, although those in 
the delay, no maintenance group tended to do slightly worse. 
Recurrence rate. In order to account for information con­
cerning all recurrences the recurrence rate was also calcu­
lated. Based on an average of 7 followup cystoscopies per 
patient the recurrence rate in the early treatment group was 
0.27 compared to 0.33 in the delayed treatment group. Using 
a 2-sided permutation test the difference was not statistically 
significant (p = 0.08). Based on an average of 8 followup 
cystoscopies per patient the recurrence rate in the mainte­
nance treatment group was 0.23 compared to 0.28 in the no 
maintenance group. The difference was not statistically sig­
nificant (p = 0.20). Table 3 presents the recurrence rate 
according to the different cross classifications of the trea t­
ment groups. The data suggest tha t patients in the delay, no 
maintenance group tended to do worse than  those in the 
other groups. While separate analyses in the 2 trials showed 
the same general trends, the effect of early treatm ent (p = 
0.016) and the poorer results in the delay, no maintenance 
group appeared to be more pronounced in trial 30832 in 
which patients tended to have a slightly better prognosis and
were treated with doxorubicin.
Tumor invasion. Based on a maximum followup of 6.5 
years and an average followup of 4 years 40 of 374 patients 
(11%) on early treatment compared to 38 of 378 (10%) on 
delayed treatment had an increase in T category to greater 
than T l during followup. Concerning maintenance tre a t­
ment, 25 of 314 patients (8%) not receiving maintenance and 
26 of 303 (9%) on maintenance had tumor invasion. Table 4 
presents the percentage of patients with tumor invasion ac­
cording to the different cross classifications of the treatm ent 
groups. For patients who were randomized a second time 
there was no significant difference in the percentage with
tumor invasion.
Distant metastases. Of 412 patients on early treatm ent 24 
(6%) compared to 17 of 412 (4%) on delayed treatm ent had 
distant metastases during followup. Concerning m ainte­
nance treatment, 13 of 314 patients (4%) not receiving m ain­
tenance and 12 of 304 (4%) on maintenance had distant 
metastases.
Second primaries. In 28 of 412 patients (7%) on early 
treatment and 25 of 412 (6%) on delayed treatm ent second 
primary tumors developed during followup. In 21 of 314 
patients (7%) not receiving maintenance compared to 15 of 
304 (5%) on maintenance second primaries developed.
Survival. Of 824 eligible patients with followup 164 (20%) 
died, including 74 (9%) of cardiovascular disease and 48 (6%) 
of malignant disease. Of 412 patients on early treatm ent 78 
(19%) compared to 86 of 412 (21%) on delayed treatm ent died. 
The difference in the duration of survival is not statistically 
significant (p = 0.60). Of 314 patients not receiving m ainte­
nance 63 (20%) and of 304 patients on maintenance 53 (17%) 
died. The difference in the duration of survival is not s ta tis­
tically significant (p = 0.41).
Table 5 presents the percentage of patients in whom me­
tastases developed, who presented with a second primary 
tumor and who died according to the different cross classifi­
cations of the treatm ent groups. For the patients who were 
randomized a second time there was no significant difference 
among the 4 groups. Figure 2 presents the duration of sur­
vival by treatment group. For the patients who were random­
ized a second time there was no significant difference in the 
duration of survival.
Adjustment for prognostic factors. The prognostic impor­
tance of the following factors was studied: number of tu ­
mors—1, 2 to 3, greater than  3; previous recurrence rate— 
primary, recurrence less than  1 per year, recurrence 1 or 
more per year; T category—Ta, Tl; size of largest tumor 
diameter—leas than 3 cm., 3 cm. or more; tumor sta tus— 
primary, recurrent; grade—1, 2 to 3; protocol—30831 (mito­
mycin C), 30832 (doxorubicin); age—less than 50 years, 50 or 
older; sex—male, female; first randomization— early trea t­
ment, delayed treatment; second randomization—no m ainte­
nance, maintenance; and treatm ent interaction— delayed, no 
maintenance, other.
The prognostic importance of these factors on the recur­
rence rate was studied in a univariate analysis using the 
permutation test and then in a multivariate linear logistic 
regression model taking as an end point the number of pos­
itive cystoscopies divided by the total number of cystoscopies. 
Univariate analyses showed the first 7 variables to be of 
prognostic importance (p <0.01). The multivariate model 
retained the first 4 variables as being the most significant
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Number of pts at risk at the corresponding times:
160 106 67 53 41 19 3 0 E-NM
150 94 66 54 38 19 5 0 E-M
154 108 60 45 33 11 2 0 D-NM
153 104 75 52 43 20 4 0 D-M
64 0 0 0 0 0 0 0 Early only
71 1 0 0 0 0 0 0 Delay only
Fig. 1. Time to first recurrence according to different cross classifications of treatment groups. E-NM, early treatment, no maintenance. 
E-M, early treatment, maintenance. D-NMy delayed treatment, no maintenance. D-M, delayed treatment, maintenance.
Table 3. Recurrence rate by treatment group
Treatment Group No. Pts. RecurrenceRate/Yr.
Early treatment, no maintenance 160 0.23
Early treatment, maintenance 150 0.25
Delayed treatment, no maintenance 154 0.33
Delayed treatment, maintenance 153 0.22
Early treatment only 64 1.20
Delayed treatment only 71 1.71
Early treatment, no maintenance versus delayed treatment, no maintenance 
p = 0.01; early treatment, maintenance versus delayed treatment, no main­
tenance p ~ 0.09 and delayed treatment, maintenance versus delayed treat­
ment, no maintenance p = 0.01.
Table 4. Invasion (greater than T l) by treatment group
Treatment Group No. Pts. No. Invasion (%)
Early treatment, no maintenance 160 14 (9)
Early treatment, maintenance 150 15 (10)
Delayed treatment, no maintenance 154 11 (7)
Delayed treatment, maintenance 153 11 (7)
Early treatment only 64 11 (17)
Delayed treatment only 71 16 (23)
(all p <0,001). Inclusion of the other potential prognostic 
factors did not improve the fit (p >0.05). Inclusion of either 
treatment variable by itself significantly improved the fit of 
the model: early treatment (p = 0.008), maintenance treat­
ment (p = 0.03). When both of these treatment variables 
were included in the model only maintenance treatment re­
mained significant (maintenance p = 0.03, early p = 0.095).
Table 5. Distant metastases, second primary, survival by
treatment group
Treatment Group No.Pts.
No.
Distant
Metastases
(%)
No. Second 
Primary 
(%)
No.
Deaths
(%)
Early treatment, no 160 7(4) 11 (7) 30 (19)
maintenance
Early treatment, 151 8(5) 10 (7) 29 (19)
maintenance
Delayed treatment, no 154 6(4) 10 (6) 33 (21)
maintenance
Delayed treatment, 153 4(3) 5 (3) 24(16)
maintenance
Early treatment only 101 9(9) 7 (7) 19(19)
Delayed treatment only 105 7(7) 10 (10) 29 (28)
For patients who were randomized a second time inclusion 
of a treatment interaction term (delay, no maintenance ver- 
sus other) significantly improved the model (p = 0.001). 
Thus, after adjustment of the prognostic factors patients in 
the delay, no maintenance arm had a significantly higher 
recurrence rate than the other patients.
Considering the 4 most important prognostic factors, risk 
groups were formed based on the number of poor prognostic 
factors (more than 1 tumor, recurrence, Tl, 3 cm. or more) a 
patient possessed. Patients were divided into 4 risk groups 
with differing prognoses as shown in table 6, While the same 
trends were seen with each of the 4 risk groups, the greatest 
treatment benefit appeared in patients with just 1 poor factor 
(the best prognosis group with no poor factor had too few
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DURATION OF SURVIVAL 30831/32
1
TOTAL FAILURE TREATMENT
159 30 E-NM
151 29 E-M
153 33 D-NM
153 24 D-M
101 19 Eariy only
105 29 Delay only
Number of pts at risk at the corresponding times:
I ____________
ENM
Early only 
EM
DM
DNM
(•
7 YEARS
159 149 132 116 95 51 8 0
151 140 125 108 79 42 9 0
153 146 127 107 84 41 5 0
153 143 127 109 91 45 9 0
101 59 53 41 30 15 2 0
105 69 58 48 37 21 4 0
E-NM
E-M
D-NM
D-M
Early only 
Delay only
Fig, 2. Duration of survival by treatment groups. E-NM, early treatment, no maintenance. E-M , early treatm ent maintenance. D-NM t 
delayed treatment, no maintenance. D-M, delayed treatment, maintenance.
Table 6. Risk groups based on poor prognostic factors
No. Poor Factors No. Pts. Recurrence Rate
None 129 0.09
1 231 0.20
2 289 0.36
3 or 4 171 0.63
recurrences to detect any differences). It is in the group with 
just 1 poor factor that patients with delay, no maintenance 
had the highest recurrence rate relative to the other patients 
who were randomized a second time. Figure 3 presents the 
duration of survival by risk group. The difference is signifi­
cant based on a log rank test for linear trend (p = 0.005). The 
greatest difference was noted between patients with a max­
imum of 1 poor factor compared to those with 2 or more poor 
factors.
DISCUSSION
Administration of adjuvant intravesical chemotherapy af­
ter transurethral resection of superficial bladder cancer 
(stages Ta, Tl) has become a common practice to try to reduce 
the high recurrence rate of these tumors and possibly to 
reduce progression towards invasive cancer. Most of the pub­
lished studies have confirmed that intravesical treatment 
can reduce the short and intermediate term incidence of 
recurrence but they have failed to demonstrate long-term 
reduction of the risk of progression towards invasive can­
cer.4“11 The most popular cytostatic agents used for intra­
vesical treatment are thiotepa, mitomycin C and doxorubicin, 
while bacillus Calmette-Guerin (BCG) acts as an immuno- 
therapeutic agent. Most of the prospective comparative trials 
have failed to demonstrate the superiority of a single cyto­
toxic agent over another. There is some evidence that BCG 
could be superior.1,12,13 Intravesical chemotherapy has been 
administered following empiric schemes and many questions 
remain unanswered concerning the ideal method of admin­
istration of the drugs. Among these questions are when 
should the adjuvant treatment start and for how long should 
it be given.
There are different possible explanations for recurrence of 
the tumors. Incomplete resection can leave tumors or parts of 
tumors that are at the origin of regrowth. In EORTC protocol 
30790, 75% of the early recurrences were at the same site as 
the previous tumors.1 Implantation of floating neoplastic 
cells was a concept first advanced in 1903 by Albarran and 
Imbert,14 and it was demonstrated through an animal exper­
iment performed by Soloway et al.15,16 It is also supported by 
the results of some clinical trials that indicate that a single 
instillation of a cytostatic agent at the time of transurethral 
resection is able to reduce the recurrence rate compared 
to resection alone.17,18 In patients with papillary disease 
hyperplasia, atypia or dysplasia may be discovered in appar­
ently normal areas of the bladder and recurrences are more 
frequent in these cases than in those without urothelial ab­
normalities. 19 ”22
If implantation and incomplete resection are responsible 
for some true recurrences, an early (and intensive) regimen
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171 154 137 107 72 33 7 0 3-4
of instillations after transurethral resection should be recom­
mended to destroy the floating cells (or the residual papillary 
tumors). If urothelial instability is the major cause of subse­
quent tumors, a long-term intravesical treatment is advised 
to destroy the abnormal cells that appear in different areas of 
the bladder.12,16,23-25
The literature provides some data about the value of early 
and/or long-term instillations but there are few prospective 
randomized trials comparing the time of first instillation and 
the duration of treatment. Some studies favor immediate 
treatment after transurethral resection.12,26-'29 The results 
of a Medical Research Council study comparing early thio- 
tepa, delayed thiotepa and no treatment showed a 5% lower 
incidence of recurrence in the control group than in the 
treatment groups.30 There are no studies on early intraves­
ical treatment with BCG; an interval of 15 to 30 days be­
tween transurethral resection and start of treatment is rec­
ommended with this drug to avoid resorption and possible 
important systemic toxicity. In regard to maintenance, the 
results of the literature are also somewhat contradictory, not 
only for chemotherapeutic agents11,31,32 but also for
BCG.33"35
In these 2 EORTC genitourinary group trials, including 
834 eligible patients, the global analysis shows that the dis­
ease free-interval was not influenced by the time of the first 
instillation nor was the recurrence rate, although there was 
a trend in favor of early treatment. However, when the in­
fluence of the time of the first instillation was analyzed 
separately for each protocol, the results were slightly differ­
ent. In protocol 30831 (mitomycin C), with relatively poor
prognostic factors, early were not better than delayed instil­
lations, while in protocol 30832 (doxorubicin), with better 
prognostic factors, early instillations provided better results 
than delayed treatment.
An analysis of the duration of the treatment did not show 
any benefit for maintenance compared to nonmaintenance 
treatment. Based on 617 patients with an average foliowup of 
38 months, there was no difference in the recurrence rate, 
which remained true when the influence of the duration of 
the treatment was analyzed separately in trials 30831 and 
30832. When both trials were combined the analysis of the 
results indicated that patients receiving early treatment 
(with or without maintenance) and those receiving delayed 
treatment with maintenance tended to have less recurrences 
than those receiving delayed and short-term treatment.
Like other trials with at least as long a folio wup, these 
protocols could not show that progression of the disease or 
survival was influenced by the treatment regimen. Since 
progression in stage may logically be related to more aggres­
sive recurrences, there is no clear explanation why adjuvant 
treatment, which is able to reduce the recurrence rate, is not 
able to reduce the incidence of progression. A probable expla­
nation is that the number of patients with progression in 
any 1 trial is too small to detect differences of reasonable 
magnitude. This finding emphasizes the need for large meta­
analyses, which have been undertaken by the EORTC geni­
tourinary group. When the results were adjusted for prog­
nostic factors, a multivariate analysis showed that treatment 
effect was highly significant and that patients in the delay,
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no maintenance arm had a significantly higher recurrence 
rate than the other patients (p = 0.001).
CONCLUSIONS
These 2 EORTC genitourinary group phase III trials indi­
cate in regard to recurrence rate that early treatment after 
transurethral resection seems to be slightly superior to de­
layed treatment (mainly in the good prognostic tumors) and 
it appears to be really effective in the no maintenance group. 
Also, maintenance alone has no benefit except in the delayed 
treatment group. These differences are at the limit of the 
statistical confidence but they become much stronger when 
the results are adjusted for prognostic factors. Results of 
early, maintenance; early, no maintenance and delayed, 
maintenance are not different but they are significantly su­
perior to those of delayed, no maintenance treatment. This 
finding indicates that when intravesical adjuvant chemo­
therapy but not BCG is considered, if early treatment is 
elected, it is not necessary to prolong it but if the first instil­
lation is not performed within 24 hours of transurethral 
resection it is wiser to maintain the treatment for a longer 
period. These 2 studies could not show that progression in 
stage or survival was influenced by the treatment regimen 
but this is probably related to the low percentage of patients 
with superficial disease who have progression towards infil­
trative disease. This finding stresses the need for large meta» 
analyses. For this reason, patients entered in these studies 
are still being followed for progression and survival.
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